TY - JOUR T1 - Second-line combination therapies in nonsmall cell lung cancer without known driver mutations JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 582 LP - 593 DO - 10.1183/16000617.00002115 VL - 24 IS - 138 AU - Maria-Virginia Bluthgen AU - Benjamin Besse Y1 - 2015/12/01 UR - http://err.ersjournals.com/content/24/138/582.abstract N2 - In advanced nonsmall cell lung cancer (NSCLC) patients, platinum-based combination chemotherapy is standard treatment in the first-line setting; however, the large majority of patients ultimately progress. For more than a decade, single-agent therapy with docetaxel, pemetrexed or erlotinib has been the standard of care after failure with platinum salts, showing some benefit over best supportive care. Nonetheless, prognosis remains poor and new second-line strategies are urgently needed. Combinations of cytotoxic agents, including rechallenge with platinum salts, do not offer clear benefit over single-agent therapy for the majority of patients. In patients without a known tumoural oncogenic driver mutation, regimens based on combinations of targeted agents have shown promising results; however, a clear role in therapeutic management is yet to be established. Some success has been reported in recent research combining a cytotoxic agent with targeted therapies.In this review, we summarise published data for the various strategies evaluated over the past decade in second-line treatment of NSCLC patients without a known driver mutation. We focus on combination treatments and consider future perspectives, including the need to identify predictive markers to support personalised therapeutic strategies.Effective second-line combinations are available but need to be integrated into a global patient management strategy http://ow.ly/SnZCC ER -